NPI 1302a-3
Alternative Names: NPI-1302a-3Latest Information Update: 04 Aug 2010
At a glance
- Originator Nereus Pharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 26 Apr 2007 Preclinical development is still ongoing
- 12 Oct 2001 Preclinical development for Rheumatoid arthritis in USA (PO)